Nurix Therapeutics, Inc. NRIX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.25M-54.0% | $13.58M+72.0% | $7.89M-82.1% | $44.06M+139% | $18.45M+38.9% | ||
| $84.14M+1.3% | $83.02M-3.6% | $86.12M+10.3% | $78.1M+12.1% | $69.66M+3.6% | ||
| $14.61M+7.0% | $13.65M+3.7% | $13.16M-7.9% | $14.28M+22.6% | $11.65M+8.7% | ||
| $98.75M+2.1% | $96.67M-2.6% | $99.28M+7.5% | $92.38M+13.6% | $81.32M+4.3% | ||
| -$92.5M-11.3% | -$83.1M+9.1% | -$91.39M-89.1% | -$48.32M+23.1% | -$62.86M+2.8% | ||
| -1,479.4%-867pp | -612%+546pp | -1,157.7%-1,048pp | -109.7%+231pp | -340.7%+146pp | ||
| -$87.17M-11.4% | -$78.22M+9.5% | -$86.42M-98.8% | -$43.46M+22.9% | -$56.35M+3.8% | ||
| -1,394.3%-818pp | -576.1%+519pp | -1,094.8%-996pp | -98.7%+207pp | -305.4%+135pp | ||
| -$0.79+4.8% | -$0.83+19.4% | -$1.03-98.1% | -$0.52+22.4% | -$0.67+10.7% | ||
| -$90.3M-11.5% | -$80.98M+9.4% | -$89.36M-93.9% | -$46.08M+23.9% | -$60.51M+2.6% | ||
| -1,444.3%-848pp | -596.4%+536pp | -1,132%-1,027pp | -104.6%+223pp | -327.9%+140pp | ||
| -$92.5M-11.3% | -$83.1M+9.1% | -$91.39M-89.1% | -$48.32M+23.1% | -$62.86M+2.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Nurix Therapeutics, Inc.'s revenue?
- Nurix Therapeutics, Inc. (NRIX) generated $71.8M in revenue over the trailing twelve months, up 27.2% year over year.
- Is Nurix Therapeutics, Inc. profitable?
- Nurix Therapeutics, Inc. is not currently profitable: it reported a net loss of $295.3M over the trailing twelve months, a -411.4% net margin.
- What is Nurix Therapeutics, Inc.'s earnings per share?
- Nurix Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-3.17.
- Where does Nurix Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
